EN IT

Targeting unmet needs in personalized oncology

XEPTAGEN SpA is engaged in the discovery and validation of novel molecular markers to improve the clinical management of cancer patients by creating innovative diagnostic tools that may allow a personalized treatment.

Latest Product Literature

Relapse after direct-acting antivirals (DAAs) in cirrhotic patients with hepatitis C is highly related to development of liver cancer. EASL International Liver Congress (ILC). Amsterdam, Holland. 2017.
Comparison between de-novo occurence and recurrence of hepatocellular carcinoma (HCC) after direct-acting antivirals (DAAs) in cirrhotic patients with hepatitis C: a real-life cohort study. EASL HCC Summit. Geneva, Switzerland. 2017.
Clinical validation of the iXip index in avoiding unnecessary prostate biopsy: results from a prospective multicenter study involving 426 patients. Cancer Treat Res Comm. 10:40-45. 2017.

Utility of SCCA-IgM levels in the prediction of hepatocellular carcinoma in cirrhotic patients. EASL HCC Summit. Geneva, Switzerland. 2017.
Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in hepatocellular carcinoma patients. Scand J Clin Lab Invest. Epub:1-6. 2017.

Squamous Cellular Carcinoma Antigen serum determination as a biomarker of Barrett esophagus and esophageal cancer: a phase III study. J. Clin. Gastroenterol.. E-pub ahead of print. 2017.


Press Releases

RSS Feed Widget

Youtube

Tweets by Xeptagen